Last reviewed · How we verify
NCT07235878
12-week Magnesium Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being
NA trial testing Placebo in Perimenopause in 58 participants. Not yet recruiting.
1 August 2026
Quick facts
| Lead sponsor | Northumbria University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 58 |
| Start date | 17 November 2025 |
| Primary completion | 1 August 2026 |
| Estimated completion | 1 August 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Placebo
- Magnesium hydroxide 375mg
Conditions studied
- Perimenopause — all drugs for Perimenopause →
- Perimenopausal Women — all drugs for Perimenopausal Women →
- Perimenopause, Climacteric Syndrome — all drugs for Perimenopause, Climacteric Syndrome →
Sponsor
Northumbria University
Who can join
Adults 40 to 60, female only, with Perimenopause or Perimenopausal Women. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Perimenopause is a transition phase into menopause, characterised by menopausal symptoms while menstrual periods are still occurring. Common symptoms of perimenopause include hot flushes, night sweats, mood swings, anxiety, sleep disturbances, fatigue, and cognitive difficulties. These symptoms can be both frequent and intense, with the potential to significantly deteriorate women's quality of life. Despite an increase in public discourse around menopause, there are still large gaps in knowledge. Previous literature has suggested a relationship between diet and menopause management. However, studies in this area are limited and women often rely on social media for advice on supplements to address menopause complaints. One supplement that has received a lot of attention with purported benefits for menopause is magnesium, primarily due to its links to energy and or/sleep, however no studies have explored psychological effects of magnesium supplementation in perimenopause. The aim of this study is to explore the effects of 12-weeks magnesium supplementation on perimenopause symptoms, cognition, sleep, and psychological well-being.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07235878
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Perimenopause
Currently open trials in the same condition.
- NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
- NCT07272174 — Exercise in Perimenopause to Improve Cognitive Health · NA · recruiting
- NCT07472881 — Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women · NA · recruiting
- NCT07135232 — The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. · NA · recruiting
- NCT07393672 — Effects of Hemp-Derived Cannabinoids on Menopause Symptoms · Phase 2 · recruiting
Other Northumbria University trials
Trials by the same sponsor.
- NCT07501611 — Acute Cardiovascular Effects of Transcutaneous Auricular Vagus Nerve Stimulation · NA · not yet recruiting
- NCT07242430 — 12-week Multi-vitamin/Mineral Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being · NA · not yet recruiting
- NCT07297485 — Evaluating the Level of Agreement Between Goniometer Measurements and Algorithm to Determine Wall Squat Position · completed
- NCT06967454 — Manipulation of Whey Permeate Formulation for Better Fluid Retention. · NA · completed
- NCT06780774 — Investigating the Acute and Chronic Effects of a Supplement Containing Caffeine, Vitamins, Minerals and Botanical Extrac · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07235878 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Northumbria University
- Last refreshed: 19 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07235878.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing